Oncology Based In-vivo CRO Market Analysis By Indication (Blood cancer, Solid tumor), By Model (Syngeneic model, Patient Derived Xenograft (PDX), Xenograft), By Region, And Segment Forecasts, 2014 - 2025

The global oncology based in-vivo CRO market is expected to reach USD 1.5 billion by 2025, according to a new report by Grand View Research, Inc. The use of Contract Research Organization (CRO) oncology services helps the manufacturers/sponsors to provide complete attention on the production capacity and at enhancing their in-house processes.
Furthermore, the pressure from the increasing competition due to patent expirations, rapid growth of generics, and introduction of biosimilar equivalents are propelling the pharmaceutical companies to take the aid of such organizations. Hence, it can be predicted that the oncology based in-vivo CRO market may witness lucrative growth over the forecast period.
Another factor propelling growth is the increasing incidence of cancer, and high failure rate of existing treatment options. According to statistics published by the World Health Organization (WHO), approximately 8.2 million deaths are recorded each year from cancer, which accounts for 13.0% deaths worldwide.
Further key findings from the study suggest:
‧ Based on indication, solid tumors are expected to dominate the market as of 2016. Furthermore, it is anticipated to grow at the fastest CAGR owing to the factors such as growing incidence rate, augmenting research for tumors in organs such as breast, and liver, and technological advancement offered by key industry players.
‧ Solid tumors are analyzed by means of models such as xenograft, Patient Derived Xenografts (PDX), and syngeneic. The PDX models are expected to witness lucrative growth over the forecast period and capture over 40.0% of the market share by 2025.
‧ Geographic expansion into Asia Pacific countries by well-established players is anticipated to promote the fastest growth for the region. India is one the most lucrative country owing to presence of service tax exemption and venture capital based funding for CROs.
‧ Few of the industry players for the oncology based in-vivo CRO market are The Jackson Laboratory, Covance, Taconic Biosciences, Charles River Laboratory, EVOTEC, Wuxi AppTec, and ICON Plc.
‧ A common trend observed is the rising partnerships among CROs to offer bundle packages of services to sponsors. For instance, In May 2017, CRL International, Inc. announced their partnership with OcellO, established in Netherlands. According to this partnership, CRL would be utilizing the latter’s PDX model capabilities in order to expand their oncology based drug discovery service portfolio.

Table of Content
Chapter 1 Research Methodology
1.1 Information Procurement
1.2 Data Analysis
1.3 Country Wise Market Calculation
1.3.1 Country wise market: Base estimates
1.3.2 Global market: CAGR calculation
1.4 List of Secondary Sources
Chapter 2 Executive Summary
2.1 Market Snapshot, 2016 (USD Million)
Chapter 3 Oncology in-vivo CRO Market Variables, Trends, & Scope
3.1 Market Segmentation & Scope
3.2 Market Size And Growth Prospects
3.3 Market Driver Analysis
3.3.1 Focus on core competencies by the pharmaceutical players
3.3.2 Accelerating time to market
3.4 Market Restraint Analysis
3.5 Key Opportunities Prioritized
3.6 Industry Analysis Porter’s
3.7 Oncology based in-vivo CRO PESTEL Analysis
Chapter 4 Oncology in-vivo CRO Market: Indication Estimates & Trend Analysis
4.1 Oncology in-vivo CRO Market: Indication Movement Analysis
4.2 Blood cancer
4.2.1 Blood cancer market estimates and forecasts, 2014 - 2025 (USD Million)
4.3 Solid tumors
4.3.1 Solid tumors market estimates and forecasts, 2014 - 2025 (USD Million)
4.3.1.1 Syngeneic model based solid tumor market estimates and forecasts, 2014 - 2025 (USD Million)
4.3.1.2 PDX based solid tumor market estimates and forecasts, 2014 - 2025 (USD Million)
4.3.1.3 Xenograft based solid tumor market estimates and forecasts, 2014 - 2025 (USD Million)
4.4 Other
4.4.1 Other market estimates and forecasts, 2014 - 2025 (USD Million)
Chapter 5 Oncology in-vivo CRO Market: Regional Estimates & Trend Analysis, by Indication
5.1 Oncology in-vivo CRO Market Share by Region, 2016 & 2025
5.2 North America
5.2.1 Oncology in-vivo CRO market estimates and forecasts, 2014 - 2025
5.2.2 U.S.
5.2.2.1 Oncology in-vivo CRO market estimates and forecasts, by indication, 2014 - 2025 (USD Million)
5.2.3 Canada
5.2.3.1 Oncology in-vivo CRO market estimates and forecasts, by indication, 2014 - 2025 (USD Million)
5.3 Europe
5.3.1 Oncology in-vivo CRO market estimates and forecasts, 2014 - 2025
5.3.2 UK
5.3.2.1 Oncology in-vivo CRO market estimates and forecasts, by indication, 2014 - 2025 (USD Million)
5.3.3 Germany
5.3.3.1 Oncology in-vivo CRO market estimates and forecasts, by indication, 2014 - 2025 (USD Million)
5.4 Asia Pacific
5.4.1 Oncology in-vivo CRO market estimates and forecasts, 2014 - 2025
5.4.2 Japan
5.4.2.1 Oncology in-vivo CRO market estimates and forecasts, by indication, 2014 - 2025 (USD Million)
5.4.3 China
5.4.3.1 Oncology in-vivo CRO market estimates and forecasts, by indication, 2014 - 2025 (USD Million)
5.5 Latin America
5.5.1 Oncology in-vivo CRO market estimates and forecasts, 2014 - 2025
5.5.2 Brazil
5.5.2.1 Oncology in-vivo CRO market estimates and forecasts, by indication, 2014 - 2025 (USD Million)
5.5.3 Argentina
5.5.3.1 Oncology in-vivo CRO market estimates and forecasts, by indication, 2014 - 2025 (USD Million)
5.6 MEA
5.6.1 Oncology in-vivo CRO market estimates and forecasts, 2014 - 2025
5.6.2 South Africa
5.6.2.1 Oncology in-vivo CRO market estimates and forecasts, by indication, 2014 - 2025 (USD Million)
5.6.3 Saudi Arabia
5.6.3.1 Oncology in-vivo CRO market estimates and forecasts, by indication, 2014 - 2025 (USD Million)
Chapter 6 Competitive Landscape
6.1 Strategy Framework
6.2 Company Profiles
6.2.1 Charles River Laboratory (CRL)
6.2.1.1 Company overview
6.2.1.2 Financial performance
6.2.1.3 Product benchmarking
6.2.1.4 Strategic initiatives
6.2.2 ICON Plc
6.2.2.1 Company overview
6.2.2.2 Financial performance
6.2.2.3 Product benchmarking
6.2.2.4 Strategic initiatives
6.2.3 Covance
6.2.3.1 Company overview
6.2.3.2 Financial performance
6.2.3.3 Service benchmarking
6.2.3.4 Strategic initiatives
6.2.4 Eurofins Scientific
6.2.4.1 Company overview
6.2.4.2 Financial performance
6.2.4.3 Product benchmarking
6.2.4.4 Strategic initiatives
6.2.5 Taconic Biosciences
6.2.5.1 Company overview
6.2.5.2 Financial performance
6.2.5.3 Product benchmarking
6.2.5.4 Strategic initiatives
6.2.6 Crown Bioscience
6.2.6.1 Company overview
6.2.6.2 Financial performance
6.2.6.3 Product benchmarking
6.2.6.4 Strategic initiatives
6.2.7 Toxikon, Inc.
6.2.7.1 Company overview
6.2.7.2 Financial performance
6.2.7.3 Product benchmarking
6.2.7.4 Strategic initiatives
6.2.8 WuXi AppTec
6.2.8.1 Company overview
6.2.8.2 Financial performance
6.2.8.3 Product benchmarking
6.2.8.4 Strategic Initiatives
6.2.9 EVOTEC
6.2.9.1 Company overview
6.2.9.2 Financial performance
6.2.9.3 Product benchmarking
6.2.9.4 Strategic initiatives
6.2.10 The Jackson Laboratory
6.2.10.1 Company overview
6.2.10.2 Financial performance
6.2.10.3 Product benchmarking
6.2.10.4 Strategic initiatives